الفهرس 
Introduction and Aim of the workOnly 14 pages are availabe for public view
 |  | from | 171 |  |  |
| | | from | 171 | | |
Abstract
This study aimed to Assess the level of expression of survivin gene (BIRC5) in childhood ALL and to evaluate their association with the different demographic, clinical and laboratory data, as well as studying its role in therapy outcome (prognostic value).
The present study was carried out on 52 subjects, forty two patients with untreated de’ novo acute lymphoblastic leukemia and ten apparently healthy subjects were included in the analysis for survivin (BIRC5) expression. Patients were selected from the outpatient clinic of Minia Oncology Center and Minia University hospital, in the period from December 2011 to June 2012 and were followed up for two years.
Subjects were classified into:
group І (Patients group ):
This group consists of 42 newly diagnosed children with acute lymphoblastic leukemia, their ages ranged from 3 to 15 years with mean ± SD 8.2±3.5 and this group included 23 males (54.8%) and 19 females (45.2%). This group was sub-classified into five groups according to immunophenotyping, group ІA, ІB, ІC, ІD and group ІE. Patient group was also sub-classified according to Survivin Gene expression level into ІF (Patient with low survivin expression) and ІG (Patient with high survivin expression).
group П (Control group):
They were ten apparently healthy subjects, matched for age and sex with patient group. Their ages ranged from 4 to 15 years with mean ± SD 7.01 ± 3.4 and this group included 5 males(50%) and 5 females (50%).
Patients and control groups were subjected to the following:
Full history taking.
Consdering age, sex, fever, bleeding tendency, easy fatigability and skin rash.
Clinical examination:
General examination:
Pallor and purpura
Hepatosplenomegaly.
Lymphadenopathy.
Abdominal ultrasonography:
To detect hepatosplenomegally for patients only.
Laboratory investigations:
A)Routine investigations:
Complete blood count (CBC) determined by automated cell counter.
Examination of Leishman-stained peripheral blood smears for differential leucocytic count and assessment of blast cell number and morphology.
Lactate dehydrogenase (LDH) and uric acid levels.
Bone marrow aspiration and examination of leishman-stained smears.
Immunophenotyping for patients only on BM samples for routine panel of acute leukemia determined by Flowcytometer.
Special investigations:
Quantitative determination of Survivin gene expression by real-time PCR on BM samples.